FDA Approves New ROS1 Indication for Xalkori With Post-Marketing CDx Commitment | GenomeWeb

NEW YORK (GenomeWeb) – In approving Pfizer's non-small cell lung cancer drug Xalkori (crizotinib) last week in metastatic patients whose tumors have ROS1 gene alterations, the agency curiously didn't clear a companion diagnostic to identify this subpopulation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.